Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2005

01-08-2005 | Report

Clinical and Radiologic Assessments to Predict Breast Cancer Pathologic Complete Response to Neoadjuvant Chemotherapy

Authors: Anne F. Schott, Marilyn A. Roubidoux, Mark A. Helvie, Daniel F. Hayes, Celina G. Kleer, Lisa A. Newman, Lori J. Pierce, Kent A. Griffith, Susan Murray, Karen A. Hunt, Chintana Paramagul, Laurence H. Baker

Published in: Breast Cancer Research and Treatment | Issue 3/2005

Login to get access
Metadata
Title
Clinical and Radiologic Assessments to Predict Breast Cancer Pathologic Complete Response to Neoadjuvant Chemotherapy
Authors
Anne F. Schott
Marilyn A. Roubidoux
Mark A. Helvie
Daniel F. Hayes
Celina G. Kleer
Lisa A. Newman
Lori J. Pierce
Kent A. Griffith
Susan Murray
Karen A. Hunt
Chintana Paramagul
Laurence H. Baker
Publication date
01-08-2005
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 3/2005
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-005-2510-1

Other articles of this Issue 3/2005

Breast Cancer Research and Treatment 3/2005 Go to the issue

Invited Commentary

Breast Cancer Treatment and Cognitive Functioning: Current Status and Future Challenges in Assessment

Report

Ductal Breast Carcinomas with Whole Chromosome Gains as a Particular Subset of Near-Diploid Tumors with Different Metastasis Free Survival

Report

Attenuation of Estrogen Receptor α (ERα) Signaling by Selenium in Breast Cancer Cells via Downregulation of ERα Gene Expression

Report

A Multi-Centre Investigation Towards Reaching a Consensus on the Immunohistochemical Detection of ERβ in Archival Formalin-fixed Paraffin Embedded Human Breast Tissue

Subject Index

Subject index, Volume 92

Report

In vitro and in vivo Effects of Combination of Trastuzumab (Herceptin) and Tamoxifen in Breast Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits